Company: NCEL
Filing Date: 2025-07-29
Form Type: F-4/A
Source: 0001213900-25-068765
Chunk: 766

Company: NewcelX Ltd.
Filing Date: 2025-07-29
Form: F-4/A
Chunk 766
---
 into their potential to modulate the impact of α -synuclein. Key findings • AEX -23: Its pronounced action as an OX1R agonist combined with positive effects on neurite outgrowth at specific concentrations suggests that it may modulate neuronal health through pathways influencing α -synucleindynamics, making it a potential therapeutic candidate to improve neuronal connectivity and resilience in PD. • AEX -19: Its effects at low concentrations on neurite growth coupled with OX1R agonist activity and a moderate increase in CTSD activity suggest potential neuroprotective benefits in PD. • AEX -24: The increase in CTSD activity and agonist activity on OX1R suggests the potential to enhance α -synucleindegradation, highlighting its promising therapeutic impact on PD.

| Moore Financial Consulting |

Annex E-40

AEX -23and AEX -19, which target OX1R, show promise in modulating the effects of α -synucleinon neurons, offering potential benefits in treating synucleinopathies like PD. AEX -19and AEX -24also present intriguing possibilities due to their effects on CTSD activity, suggesting pathways for reducing α -synucleinaggregation. Further in vitroresearch and in vivopreclinical studies are necessary to elucidate the precise mechanisms, optimize dosing, and evaluate the long -termefficacy and safety of these compounds in preclinical and clinical settings. NLS Therapeutics financials: Following are the Company’s Balance sheets as of December 31, 2023, and 2022 and the Proforma Balance as of June 2024:

| $ 000’                                           |     | 30.06.2024 |   |     | 31.12.2023 |   |     | 31.12.2022 |   |
| Assets                                           |     |            |   |     |            |   |     |            |   |
| Current Assets                                   |     |            |   |     |            |   |     |            |   |
| Cash and cash equivalents                        |     |      3,753 |   |     |        898 |   |     |      8,948 |   |
| Prepaid expenses and other current assets        |     |        640 |   |     |        925 |   |     |        298 |   |
|                                                  |     |      4,392 |   |     |      1